4.95
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Naloxone Market Rises with Government Initiatives to Combat Opioid Overdose | Emergent BioSolutions, Hikma, Teva - openPR.com
Emergent to supply Narcan nasal spray in Ontario (EBS:NYSE) - Seeking Alpha
Emergent BioSolutions Gets $65M Deal for Ontario Naloxone Program - MarketWatch
Emergent BioSolutions (EBS) Secures $65M Deal with Ontario for N - GuruFocus
Emergent BioSolutions Reinforces Commitment to Opioid Emergency - GuruFocus
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health - The Manila Times
Emergent BioSolutions Lands Major $65M Deal: Ontario Chooses NARCAN to Fight Opioid Crisis - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
Emergent BioSolutions Inc. to Host Conference Call on Q1 2025 Financial Results - Nasdaq
Save The Date: Emergent BioSolutions Q1 2025 Earnings Conference Call Coming May 7 - Stock Titan
Lobbying Update: $920,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions ($EBS) Is Paying a $40M Settlement to Investors — Here’s How to Get Your Share - TradingView
Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) see US$31m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Emergent BioSolutions launches stock repurchase program - MSN
Mile Marker Continues New Business Success With Growth-Oriented Brands - Yahoo Finance
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS - Business Wire
Emergent BioSolutions sets $50 million stock buyback plan By Investing.com - Investing.com South Africa
Emergent BioSolutions Authorizes $50 Million Stock Buyback Program - MarketScreener
Emergent BioSolutions Announces Repurchase Of Up To $50 Mln Stock, Pre-market Stock Up - Nasdaq
Emergent BioSolutions sets $50 million stock buyback plan - Investing.com
$50M Stock Buyback: Emergent BioSolutions Signals Strong Confidence in Turnaround Plan - Stock Titan
Q1 Earnings Estimate for EBS Issued By HC Wainwright - MarketBeat
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (NYSE:EBS) - Seeking Alpha
SEC Form DEFA14A filed by Emergent BioSolutions Inc. - Quantisnow
Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts - Benzinga
Benign Growth For Emergent BioSolutions Inc. (NYSE:EBS) Underpins Stock's 31% Plummet - simplywall.st
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - The Manila Times
Just Awarded: Emergent BioSolutions Grants Major 72,882 Share Package to Strategic New Hire - Stock Titan
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues - Seeking Alpha
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg - The Manila Times
Breakthrough: New High-Dose Naloxone Spray Gets Health Canada Green Light as Overdose Crisis Persists - StockTitan
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions - Medical Dialogues
Emergent BioSolutions sells Baltimore facility to Syngene By Investing.com - Investing.com India
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - citybiz
Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc. - equitybulls.com
Emergent BioSolutions Completes Sale of Baltimore-Bayview Facility to Syngene International - Marketscreener.com
Emergent Biosolutions finalizes sale of Baltimore-Bayview manufacturing site to Syngene International - Marketscreener.com
Emergent BioSolutions sells Baltimore facility to Syngene - Investing.com
Emergent BioSolutions Strategic Win: $36.5M Facility Sale While Securing Future Production Rights - StockTitan
Emergent BioSolutions secures $27 million in MCM orders By Investing.com - Investing.com Australia
Emergent BioSolutions secures $27 million in MCM orders - Investing.com
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products - The Manila Times
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International - EIN News
Syngene Acquires First US Manufacturing Facility - Contract Pharma
Emergent BioSolutions Expands Global Reach with $27M Medical Defense Deal - Stock Titan
자본화:
|
볼륨(24시간):